MedTrace Logo

Vorinostat and Palliative Radiotherapy

NCT00455351 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-05-08

No results posted yet for this study

Summary

Phase I study. Side-effects when combined with standard palliative radiotherapy.

Conditions

  • Pelvic Cancer
  • Radiotherapy

Interventions

DRUG

Vorinostat

Increasing dosing, phase I

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Sigbjørn Smeland, MD,PhD · Norwegian Radium Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-03-31
Completion
2009-08-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00455351 on ClinicalTrials.gov